Werewolf Therapeutics (HOWL) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

HOWL Werewolf Therapeutics

Watchlist

1.650
-0.060-3.51%

Close Dec 13 16:00 ET

1.700
+0.050+3.03%

Post 18:49 ET

73.53MMarket Cap-1.09P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference
GlobeNewswireNov 20 08:00 ET
Werewolf Therapeutics Analyst Ratings
BenzingaNov 19 06:26 ET · Ratings
Werewolf Therapeutics Advances Innovative Cytokine Therapies
TipRanksNov 12 10:11 ET
Leerink Partners Maintains Werewolf Therapeutics(HOWL.US) With Buy Rating, Maintains Target Price $13
Moomoo NewsNov 12 03:31 ET · Ratings
Promising Potential of Werewolf Therapeutics' INDUKINE Platform Despite Challenges
TipRanksNov 12 02:45 ET
JMP Securities Maintains Werewolf Therapeutics(HOWL.US) With Buy Rating, Maintains Target Price $12
Moomoo NewsNov 11 06:31 ET · Ratings

Comments

Jaguar8

Nov 7 08:04

NEWS

$Werewolf Therapeutics (HOWL.US)$
Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
Werewolf Therapeutics (HOWL) presented interim Phase 1 clinical trial results for WTX-330, their tumor-activated IL-12 prodrug, at SITC's 39th Annual Meeting. The trial enrolled 25 patients with diverse solid tumors, showing favorable tolerability and encouraging efficacy. Key findings include a confirmed partial response in a ...

Trytosaveabit

Oct 31 07:10

Update

$Werewolf Therapeutics (HOWL.US)$ Reuters
4 mins ago
Werewolf Therapeutics Announces Promising New Development Candidate, Wtx-921, a First-of-Its-Kind Il-10 Indukine™ Molecule for Inflammatory Diseases